Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24775423 | 0.85 | OPRM1 (0.39) | OPRM1OPRK1MEN1KMT2A | |
| SCHEMBL24775422 | 0.84 | OPRM1 (0.40) | OPRM1OPRK1 | |
| SCHEMBL24775977 | 0.80 | CHRNA7 (0.37) | OPRM1OPRK1 | |
| SCHEMBL24775160 | 0.79 | CHRNA7 (0.39) | OPRM1OPRK1 | |
| SCHEMBL24775973 | 0.79 | CHRNA7 (0.39) | OPRM1OPRK1 | |
| SCHEMBL24775976 | 0.79 | CHRNA7 (0.39) | OPRM1OPRK1 | |
| SCHEMBL24853450 | 0.79 | HSP90AA1 (0.40) | MEN1KMT2A | |
| SCHEMBL24775978 | 0.78 | CHRNA7 (0.38) | OPRM1OPRK1 | |
| SCHEMBL24119547 | 0.75 | CHRNB2 (0.53) | DRD2 | |
| SCHEMBL24774514 | 0.74 | CHRNB2 (0.51) | OPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2022-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402915-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | OPRM1 4833/4885OPRK1 4318/4885DRD2 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.